Please login to the form below

Not currently logged in
Email:
Password:

Exelixis appoints Andrew Peters to newly created position

He joins the biotech as its vice president, strategy

ExelixisCalifornia, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy.

In this newly created role, Peters will work with the Exelixis leadership team to refine the company’s mid- and long-term strategy, which is focused on advancing the next generation of Exelixis medicines.

Commenting on his appointment, Michael Morrissey, president and chief executive officer of Exelixis, said: “Andrew’s extensive experience as a biotechnology industry analyst makes him a valuable addition to the Exelixis team as we work to identify potential future growth opportunities for the company.

“His familiarity with Exelixis and the biotech landscape should make for a seamless transition into his new role.”

Prior to his new role, Peters served as a director and senior analyst for Deutsche Bank Securities.

He has also held roles UBS Securities, Susquehanna International Group and Morgan Joseph & Co.

11th June 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics